QurAlis
Michael McMillan is a Scientist I at QurAlis since August 2022, previously serving as a Graduate Student Research Assistant at the University of Michigan Medical School from September 2017 to August 2022, where efforts focused on the molecular mechanisms of amyotrophic lateral sclerosis (ALS) and neurodegeneration. Michael's extensive experience includes leadership roles at miLEAD Consulting, including President and Project Manager, overseeing strategic analyses and team collaboration. Internships at Shire and research positions at the University of Massachusetts Amherst provided foundational skills in biomarker development and antibiotic resistance. Michael holds a PhD in Cell/Cellular and Molecular Biology from the University of Michigan and a BS in Biochemistry and Molecular Biology from the University of Massachusetts Amherst.
QurAlis
1 followers
QurAlis is developing precision therapeutics for ALS, a terminal disease that causes muscle paralysis through degeneration of the motor system. They are digging deep into the root causes of the multiple sub-forms of this destructive disease and focus their programs on tackling specific disease-causing mechanisms.